Merck spends $10 billion for Verona, gaining access to its COPD medication
By MICHELLE CHAPMAN
Pharmaceutical giant Merck is buying Verona Pharma, a company that focuses on respiratory diseases, in an approximately $10 billion deal.
Related Articles
-
Samsung unveils its new line of foldable devices at Unpacked -
Fewer Canadians are searching for homes in Orlando, other Florida cities, data shows -
Customers seeking deals gave Amazon’s Prime Day and competing sales a solid start -
Could renting be part of the new American dream? -
Universal’s Woodbury set for IAAPA Expo session
The deal gives Merck access to Verona Pharma’s new chronic obstructive pulmonary disease medication Ohtuvayre. U.S. regulators approved the inhaled medication more than a year ago to treat chronic obstructive pulmonary disease, or COPD, in adults.
“Ohtuvayre complements and expands our pipeline and portfolio of treatments for cardiopulmonary diseases while delivering near- and long-term growth as well as value for shareholders,” Merck & Co. Inc. Chairman and CEO Robert Davis said in a statement.